Prestige Brands Holdings, Inc.
As filed with the Securities and
Exchange Commission on December 28, 2006
Registration
No. 333-
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM S-3
REGISTRATION
STATEMENT
UNDER THE SECURITIES ACT OF
1933
PRESTIGE BRANDS HOLDINGS,
INC.
(Exact name of registrant as
specified in its charter)
|
|
|
Delaware
|
|
20-1297589
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer Identification
No.)
|
90 North Broadway
Irvington, New York
10533
(914) 524-6810
(Address, including zip code, and
telephone number, including area code, of registrants
principal executive offices)
Charles N. Jolly, Esq.
General Counsel
Prestige Brands Holdings,
Inc.
90 North Broadway
Irvington, New York
10533
(914) 524-6810
(Name, address, including zip code,
and telephone number, including area code, of agent for service)
Copies to:
|
|
|
Gary M. Brown, Esq.
Baker, Donelson, Bearman,
Caldwell & Berkowitz, PC
211 Commerce Street, Suite 1000
Nashville, Tennessee 37201
(615) 726-5763 phone
(615) 744-5763 fax
|
|
Mark A. B. Carlson, Esq.
Baker, Donelson, Bearman,
Caldwell & Berkowitz, PC
165 Madison Avenue
Memphis, Tennessee 38103
(901) 577-2274 phone
(901) 577-8163 fax
|
Approximate date of commencement of proposed sale to the
public: From time to time after the effective
date of this Registration Statement.
If the only securities being registered on this Form are to be
offered pursuant to dividend or interest reinvestment plans,
please check the following
box. o
If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to
Rule 415 under the Securities Act of 1933, other than
securities offered only in connection with dividend or interest
reinvestment plans, check the following
box. þ
If this form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act,
please check the following box and list the Securities Act
registration statement number of the earlier effective
registration statement for the same
offering. o
If this form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, please check the
following box and list the Securities Act registration statement
number of the earlier effective registration statement for the
same offering. o
If this form is a registration statement pursuant to General
Instruction I.D. or a post-effective amendment thereto that
shall become effective upon filing with the Commission pursuant
to Rule 462(e) under the Securities Act, check the
following box. o
If this form is a post-effective amendment to a registration
statement pursuant to General Instruction I.D. filed to
register additional securities or additional classes of
securities pursuant to Rule 413(b) under the Securities
Act, check the following box. o
CALCULATION OF REGISTRATION
FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposed Maximum
|
|
|
Proposed Maximum
|
|
|
|
Title of Each Class of
|
|
|
Amount to be
|
|
|
Offering Price per
|
|
|
Aggregate Offering
|
|
|
Amount of
|
Securities to be Registered
|
|
|
Registered (1)
|
|
|
Share (2)
|
|
|
Price
|
|
|
Registration Fee
|
Common Stock, par value $0.01 per
share
|
|
|
12,650,000 shares
|
|
|
$13.12
|
|
|
$165,968,000
|
|
|
$17,759
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Includes shares that the
underwriters have the option to purchase solely to cover
over-allotments, if any.
|
(2)
|
|
Estimated solely for the purpose of
calculating the registration fee pursuant to Rule 457(c)
under the Securities Act of 1933, as amended (the
Securities Act), based on the average of the high
and low prices of the common stock on the New York Stock
Exchange on December 21, 2006.
|
The registrant hereby amends this registration statement on
such date or dates as may be necessary to delay its effective
date until the registrant shall file a further amendment which
specifically states that this registration statement shall
thereafter become effective in accordance with Section 8(a)
of the Securities Act of 1933 or until this registration
statement shall become effective on such date as the Commission,
acting pursuant to said Section 8(a), may determine.
The
information in this prospectus is not complete and may be
changed. The selling stockholders may not sell these securities
until the registration statement filed with the Securities and
Exchange Commission is effective. This prospectus is not an
offer to sell these securities and it is not soliciting an offer
to buy these securities in any state where the offer or sale is
not permitted.
|
Subject to Completion Dated
December 28, 2006
PROSPECTUS
12,650,000 Shares
Prestige Brands Holdings,
Inc.
Common Stock
The selling stockholders are offering 12,650,000 shares of
our common stock. All of the shares of common stock covered by
this prospectus are being offered and sold by the selling
stockholders. We are not selling any of the shares of common
stock offered by this prospectus and, therefore, will not
receive any of the proceeds from the sale of common stock by the
selling stockholders. We are registering the resale of the
shares of common stock to satisfy registration rights we
previously granted the selling stockholders. The registration
rights agreement requires that we pay substantially all the
expenses that are incurred in connection with registering this
offering.
You should carefully read this prospectus and any information
incorporated by reference into this prospectus before you decide
to invest in our common stock.
Our common stock is traded on the New York Stock Exchange under
the symbol PBH. On December 27, 2006, the last
reported sale price of our common stock on the New York Stock
Exchange was $13.65 per share.
See Risk Factors on page 5 of this prospectus to
read about factors you should consider before buying our common
stock.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal
offense.
The date of this prospectus
is ,
2006
TABLE OF
CONTENTS
ABOUT
THIS PROSPECTUS
This prospectus is part of a registration statement that we
filed with the Securities and Exchange Commission, or the SEC.
We were required by an agreement with the selling stockholders
to file this registration statement in order for the selling
stockholders to be able to sell the common stock offered by this
prospectus.
No person is authorized to give any information or represent
anything not contained in this prospectus and the documents
incorporated by reference in this prospectus. You should rely
only on the information contained in or incorporated by
reference into this prospectus. The information contained in
this prospectus or in any document incorporated by reference is
accurate only as of its date, regardless of the time of delivery
of this prospectus or any sale of common stock. Our business,
financial condition, results of operations and prospects may
have changed since that date.
This prospectus is not an offer to sell or solicitation of an
offer to buy these shares of common stock in any circumstances
under which or jurisdiction in which the offer or solicitation
is unlawful.
The terms Prestige, we, us,
and our as used in this prospectus refer to Prestige
Brands Holdings, Inc. and its consolidated subsidiaries and,
unless the context requires otherwise, their respective
predecessors.
Our fiscal year ends on March 31 of each year. References to a
year (e.g., 2006) refer to our fiscal year that ends
on March 31 of that year.
Trademarks and trade names used in this prospectus are the
property of Prestige or its subsidiaries, as the case may be. We
have utilized the
®
symbol the first time each federally registered trademark, owned
by Prestige or its subsidiaries, appears in this prospectus.
MARKET
INFORMATION
Information regarding market share, market position and industry
data pertaining to our business contained in or incorporated by
reference into this prospectus consists of estimates based on
data and reports compiled by industry professional organizations
(including Information Resources, Inc.) and analysts, and our
knowledge of our revenues and markets.
We take responsibility for compiling and extracting, but have
not independently verified, market and industry data provided by
third parties, or by industry or general publications, and take
no further responsibility for such data. Similarly, while we
believe our internal estimates are reliable, our estimates have
not been verified by any independent sources, and we cannot
assure you as to their accuracy.
i
PROSPECTUS
SUMMARY
The following summary should be read in conjunction with, and
is qualified in its entirety by, the more detailed information,
including the information under Risk Factors and
financial statements and related notes incorporated by reference
into this prospectus. Because this is a summary, it is not
complete and may not contain all of the information that is
important to you and that you should consider before buying
shares of our common stock. Our actual results could differ
materially from those anticipated in certain forward-looking
statements contained in or incorporated by reference into this
prospectus as a result of various factors, including those set
forth under Risk Factors in our periodic reports
that we file with the SEC.
Overview
We sell well-recognized, brand name
over-the-counter
drug, household cleaning and personal care products. We operate
in attractive niche segments of these categories, which we
believe are typically overlooked by larger competitors. We view
our established retail distribution network, a low-cost
operating model and our experienced management team as a
competitive advantage that we believe will enable us to
profitably grow our presence in these niche segments. Our
fourteen major brands, set forth in the table below, have strong
levels of consumer awareness and retail distribution across all
major channels of distribution. These brands accounted for
approximately 93% of our net sales for 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Market
|
|
|
|
|
Market
|
|
|
|
|
Major Brands
|
|
Position (1)
|
|
|
Market Segment
|
|
Share (1)
|
|
|
ACV(1)
|
|
|
|
|
|
|
|
|
(%)
|
|
|
(%)
|
|
|
Over-the-Counter
Drug:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chloraseptic®
|
|
|
#1
|
|
|
Sore Throat Relief
|
|
|
47.5
|
%
|
|
|
96
|
%
|
Clear
eyes®
|
|
|
#2
|
|
|
Eye Redness Relief
|
|
|
15.2
|
|
|
|
87
|
|
Compound
W®
|
|
|
#2
|
|
|
Wart Removal
|
|
|
32.5
|
|
|
|
85
|
|
Wartner®
|
|
|
#3
|
|
|
Wart Removal
|
|
|
12.4
|
|
|
|
67
|
|
The
Doctors®
NightGuardtm
|
|
|
#1
|
|
|
Bruxism (Teeth Grinding)
|
|
|
99.6
|
|
|
|
59
|
|
Murine®
|
|
|
#3
|
|
|
Personal Ear Care
|
|
|
12.8
|
|
|
|
63
|
|
Little
Remedies®(2)
|
|
|
N/A
|
|
|
Infants and Children OTCs
|
|
|
N/A
|
|
|
|
70
|
|
New-Skin®
|
|
|
#1
|
|
|
Liquid Bandages
|
|
|
33.2
|
|
|
|
85
|
|
Dermoplast®
|
|
|
#2
|
|
|
Pain Relief Sprays
|
|
|
31.0
|
|
|
|
62
|
|
Household Cleaning:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comet®
|
|
|
#2
|
|
|
Abrasive Tub and Tile Cleaner
|
|
|
30.9
|
|
|
|
98
|
|
Chore
Boy®
|
|
|
#1
|
|
|
Soap Free Metal Scrubbers
|
|
|
33.9
|
|
|
|
40
|
|
Spic and
Span®
|
|
|
#6
|
|
|
Dilutable Cleaners
|
|
|
4.1
|
|
|
|
61
|
|
Personal Care:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cutex®
|
|
|
#1
|
|
|
Nail Polish Remover
|
|
|
28.0
|
|
|
|
93
|
|
Denorex®
|
|
|
#4
|
|
|
Medicated Shampoo
|
|
|
6.2
|
|
|
|
65
|
|
|
|
|
(1) |
|
Source: Information Resources, Inc. Market share and
market position are based on sales dollars in the
United States, as calculated by Information Resources for the
52 weeks ended November 5, 2006 in food stores, drug
stores, and mass merchandisers (excluding Wal-Mart).
ACV refers to the All Commodity Volume Food Drug
Mass Index, as calculated by Information Resources for the
52 weeks ended November 5, 2006. ACV measures the
weighted sales volume of stores that sell a particular product
out of all the stores that sell products in that market segment
generally. For example, if a product is sold by 50% of the
stores that sell products in that market segment, but those
stores account for 85% of the sales volume in that market
segment, that product would have an ACV of 85%. We believe that
ACV is a measure of a products importance to major
retailers. We believe that a high ACV evidences a products
attractiveness to consumers, as major national and regional
retailers will carry products that are attractive to their
customers. Lower ACV measures would indicate that a |
footnotes continued on following page
1
|
|
|
|
|
product is not as available to consumers because the major
retailers do not carry products for which consumer demand may
not be as high. For these reasons, we believe that ACV is an
important measure for investors to gauge consumer awareness of
our product offerings. |
|
(2) |
|
Market share information for market segments in which Little
Remedies products compete is not available from Information
Resources. |
Our products are sold through multiple channels, including mass
merchandisers and drug, grocery, dollar and club stores. This
channel mix allows us to effectively launch new products across
all distribution channels and reduces our exposure to any single
distribution channel. We focus our internal resources on
marketing, sales, customer service and product development.
While we perform the production planning and oversee the quality
control aspects of the manufacturing, warehousing and
distribution of our products, we outsource the operating
elements of these functions to well-established, lower-cost,
third-party providers. This operating model allows us to focus
our resources on marketing and product development, which we
believe enables us to achieve attractive margins while
minimizing capital expenditures and working capital requirements.
We have grown our brand portfolio by acquiring strong and
well-recognized brands from larger consumer products and
pharmaceutical companies, as well as other brands from smaller
private companies. While the brands we have purchased from
larger consumer products and pharmaceutical companies have long
histories of support and brand development, we believe that at
the time we acquired them they were considered
non-core by their previous owners and did not
benefit from the focus of senior level management or strong
marketing support. We believe that the brands we have purchased
from smaller private companies have been constrained by the
limited resources of their prior owners. After acquiring a
brand, we seek to increase its sales, market share and
distribution in both new and existing channels through our
established retail distribution network. We pursue this growth
through increased advertising and promotion, new marketing
strategies, improved packaging and formulations and innovative
new products.
Our
History
Originally formed in 1996, as a joint venture of Medtech Labs
and The Shansby Group, to acquire
over-the-counter
drug brands from American Home Products, our Company has been
led since 2001 by our chairman, and chief executive officer,
Peter Mann, and chief financial officer, Peter Anderson. Since
2001, our portfolio of brand name products has expanded from
over-the-counter
drugs to include household cleaning and personal care products.
We have added brands to our portfolio principally by acquiring
strong and well-recognized brands from larger consumer products
and pharmaceutical companies. In February 2004, GTCR Golder
Rauner II, LLC (GTCR), a private equity firm,
acquired our business from the original founders, as well as the
Spic and Span business, with Messrs. Mann and Anderson
continuing to lead the management team.
In April 2004, we acquired Bonita Bay Holdings, Inc., the parent
holding company of Prestige Brands International, Inc. which
conducted its business under the Prestige name.
After we completed the Bonita Bay acquisition, we began to
conduct our business under the Prestige name. The
Bonita Bay portfolio included the following major brands:
Chloraseptic, Comet, Clear eyes and Murine.
In October 2004, we acquired the rights to the Little
Remedies brands through our purchase of Vetco, Inc. Vetco is
engaged in the development, distribution and marketing of
pediatric
over-the-counter
healthcare products, primarily marketed under the Little
Remedies brand name. Vetcos products include Little
Noses®
nasal products, Little
Tummys®
digestive health products, Little
Colds®
cough/cold remedies and Little Remedies New Parents
Survival Kits. The Little Remedies products deliver
relief of common childhood ailments without unnecessary
additives such as saccharin, alcohol, artificial flavors,
coloring dyes or harmful preservatives.
In October 2005, we acquired the rights to the Chore
Boy®brand
of metal cleaning pads, scrubbing sponges, and non-metal soap
pads. The brand has over 84 years of history in the
scouring pad and cleaning accessories categories. We believe
this brand will benefit from our business model and create
synergies in our household cleaning segment.
In November 2005, we acquired Dental Concepts LLC, a marketer of
therapeutic oral care products sold under The
Doctors®
brand. The business is driven primarily by two niche segments,
bruxism (nighttime teeth grinding)
2
and interdental cleaning. The
Doctors®
NightGuard brand is the first and only FDA-approved OTC
treatment for bruxism and The
Doctors®
BrushPicks®
are disposable interdental toothpicks. We expect that The
Doctors®
product line will benefit from our business model of outsourcing
manufacturing and increasing awareness though targeted marketing
and advertising. Additionally, we anticipate benefits associated
with our ability to leverage certain economies of scale and the
elimination of redundant operations.
On September 21, 2006, we acquired the
Wartner®
brand of
over-the-counter
wart treatment products from Lil Drug Store Products, Inc.
for approximately $31 million in cash. In addition to the
purchase price, we assumed contingent earn out payments
approximating $5 million to a former owner. Wartner is the
#3 brand in the U.S.
over-the-counter
wart treatment category. The Wartner line consists of two
products which compete within the cryosurgical segment of the
wart treatment products category. These include Wartner Original
for common and plantar warts and Wartner Plantar for stubborn
plantar warts. As part of the acquisition, we acquired the
rights to Wartner for all of North America, including Canada and
Mexico. Wartner is a patented product in the U.S. and has a
patent application pending in Canada where it also has a leading
position in the category.
Recent
Developments
Two of our senior officers, Michael Fink and Eric Millar, are
nearing retirement age, and either or both may retire before the
end of 2007. We have identified potential candidates to replace
each of these executives upon their retirement and do not
believe that their retirement will result in any material
disruption to the orderly management of our business.
Corporate
Information
Our principal executive office is located at 90 North Broadway,
Irvington, New York 10533, and our telephone number is
(914) 524-6810.
Our website is www.prestigebrandsinc.com. Information on our
website is not a part of this prospectus and is not incorporated
in this prospectus by reference.
3
THE
OFFERING
|
|
|
Common stock offered by the selling stockholders |
|
12,650,000 shares |
|
Common stock to be outstanding after this offering |
|
50,005,289 shares |
|
Use of proceeds |
|
We will not receive any proceeds from the sale of shares of our
common stock by the selling stockholders. |
|
Dividends |
|
We have not in the past paid, and do not expect for the
foreseeable future, to pay dividends on our common stock.
Instead, we anticipate that all of our earnings in the
foreseeable future will be used in the operation and growth of
our business. Any future determination to pay dividends will be
at the discretion of our board of directors and will depend
upon, among other factors, our results of operations, financial
condition, capital requirements and contractual restrictions,
including restrictions under our then existing debt instruments,
and any other considerations our board of directors deems
relevant. |
|
Risk Factors |
|
Investing in our common stock involves substantial risks. You
should carefully read and consider the information set forth
under Risk Factors and all other information
contained in or incorporated by reference into this prospectus
before investing in our common stock. |
|
New York Stock Exchange symbol |
|
PBH |
The number of shares of common stock to be outstanding after
this offering is based on the number of shares outstanding as of
November 30, 2006 and excludes 4,666,300 additional
shares of common stock reserved for future grants or awards
under our 2005 Long-Term Equity Incentive Plan.
4
RISK
FACTORS
An investment in our securities is risky. Before making a
decision about investing in our securities, you should read and
consider carefully the risk factors and information contained in
our periodic reports filed with the SEC, which are incorporated
by reference in this prospectus. Additional risks and
uncertainties not presently known to us or that we currently
deem immaterial may also impair our business operations. If any
of the risks or uncertainties described in our periodic reports
filed with the SEC or any such additional risks and
uncertainties actually occur, our business, results of
operations and financial condition could be materially and
adversely affected. In that case, the trading price of the
securities being offered by this prospectus and any applicable
prospectus supplement could decline, and you might lose all or
part of your investment. You should consider these risk factors
when you read forward-looking statements contained elsewhere or
incorporated by reference in this prospectus.
CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Some of the statements contained and incorporated by reference
in this prospectus and in particular, statements found under the
captions Risk Factors and Managements
Discussion and Analysis of Financial Condition and Results of
Operations in our Annual Report on
Form 10-K
for the year ended March 31, 2006 and in our Quarterly
Reports on
Form 10-Q
for the quarters ended June 30, 2006 and September 30,
2006 that are not historical in nature may constitute
forward-looking statements within the meaning of
Section 27A of the Securities Act and Section 21E of
the Securities Exchange Act of 1934 (the Exchange
Act). We intend such forward-looking statements to be
covered by the safe harbor provisions for forward-looking
statements contained in the Private Securities Litigation Reform
Act of 1995, and we are including this statement for purposes of
invoking these safe harbor provisions. These forward-looking
statements, which are based on certain assumptions and describe
our future plans, strategies and expectations on revenue growth,
expansion opportunities, strategic acquisitions, operating costs
and expenses, and industry trends, are generally identifiable by
use of the words believe, expect,
intend, anticipate,
estimate, forecast, project,
plan, will continue, will likely
result or similar expressions. Our ability to predict the
results or the actual effect of future plans or strategies is
inherently uncertain. Our actual results could differ materially
from those indicated in these statements as a result of matters
discussed herein, as well as certain risk factors more fully
discussed under Risk Factors in our periodic reports
filed with the SEC.
Because actual results may differ from those predicted by such
forward-looking statements, you should not rely on such
forward-looking statements when deciding whether to buy, sell or
hold our securities. We undertake no obligation to update these
forward-looking statements in the future.
USE OF
PROCEEDS
We will not receive any proceeds from the sale of shares of our
common stock by the selling stockholders.
We, however, as required by the registration rights agreement
between us and the selling stockholders, will pay substantially
all of the costs, fees and expenses incurred in effecting the
registration of the shares of common stock covered by this
prospectus, including, but not limited to, all registration and
filing fees, fees and expenses of our counsel and our
accountants and reasonable fees and expenses of counsel to the
selling stockholders. The selling stockholders will pay any
brokerage expenses incurred by the selling stockholders in
connection with their sales of common stock.
5
PRICE
RANGE OF COMMON STOCK
Our common stock is listed on the New York Stock Exchange under
the symbol PBH. Public trading of our common stock
commenced on February 10, 2005. Prior to that date, there
was no public trading market for our common stock.
The following table sets forth the high and low sales intra day
prices per share for our common stock as reported on the New
York Stock Exchange for each fiscal quarter since February 2005.
|
|
|
|
|
|
|
|
|
Fiscal Year Ended March 31, 2005
|
|
High
|
|
Low
|
|
Fourth quarter ended March 31
(commencing February 10, 2005)
|
|
$
|
18.80
|
|
|
$
|
17.15
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year Ended March 31, 2006
|
|
High
|
|
|
Low
|
|
|
First quarter ended June 30
|
|
$
|
19.67
|
|
|
$
|
15.80
|
|
Second quarter ended
September 30
|
|
$
|
21.15
|
|
|
$
|
10.10
|
|
Third quarter ended
December 31
|
|
$
|
12.50
|
|
|
$
|
9.37
|
|
Fourth quarter ended March 31
|
|
$
|
13.13
|
|
|
$
|
10.22
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year Ending March 31, 2007
|
|
High
|
|
|
Low
|
|
|
First quarter ended June 30
|
|
$
|
12.90
|
|
|
$
|
8.25
|
|
Second quarter ended
September 30
|
|
$
|
11.55
|
|
|
$
|
8.50
|
|
Third quarter ending
December 31 (through December 27, 2006)
|
|
$
|
13.73
|
|
|
$
|
10.77
|
|
On December 27, 2006, the last reported sale price of our
common stock on the New York Stock Exchange was $13.65 per
share. As of December 15, 2006, there were approximately 57
holders of record of our common stock.
DIVIDEND
POLICY
We have not in the past paid, and do not expect for the
foreseeable future, to pay dividends on our common stock.
Instead, we anticipate that all of our earnings in the
foreseeable future will be used in the operation and growth of
our business. Any future determination to pay dividends will be
at the discretion of our board of directors and will depend
upon, among other factors, our results of operations, financial
condition, capital requirements and contractual restrictions,
including restrictions under our then existing debt instruments,
and any other considerations our board of directors deems
relevant.
6
SELLING
STOCKHOLDERS
Information about the potential selling stockholders who offer
securities under the registration statement of which this
prospectus is a part will be set forth in prospectus
supplements, post-effective amendments
and/or
filings we make with the SEC under the Exchange Act that are
incorporated by reference. Each prospectus supplement,
post-effective amendment
and/or
filing under the Exchange Act will include the following
information:
|
|
|
|
|
the number of shares of common stock then held by the selling
stockholders;
|
|
|
|
the number of shares of common stock then being offered by the
selling stockholders;
|
|
|
|
the number of shares (and, if one percent or more, the
percentage) of common stock owned by the selling stockholders
after completion of the offering; and
|
|
|
|
any material relationship between us and our selling
stockholders during the past three years.
|
7
DESCRIPTION
OF CAPITAL STOCK
General
Matters
Our total amount of authorized capital stock is
250,000,000 shares of common stock, $0.01 par value
per share, and 5,000,000 shares of preferred stock,
$0.01 par value per share. As of November 30, 2006,
50,005,289 shares of common stock and no shares of
preferred stock were issued and outstanding. The discussion set
forth below describes the most important terms of our capital
stock, amended and restated certificate of incorporation and
by-laws. Because it is only a summary, it does not contain all
of the information that may be important to you. For a complete
description you should refer to our amended and restated
certificate of incorporation and bylaws, copies of which we have
previously filed with the SEC, and to the applicable provisions
of the Delaware General Corporation Law.
Common
Stock
All of our existing common stock is, and the shares of common
stock being offered by the selling stockholders pursuant to this
prospectus are, validly issued, fully paid and nonassessable.
Set forth below is a brief discussion of the principal terms of
our common stock.
Dividend Rights. Subject to preferences that
may apply to shares of preferred stock outstanding at the time,
holders of outstanding shares of common stock are entitled to
receive dividends out of assets legally available at the times
and in the amounts as the board of directors may from time to
time determine. For more information, see Dividend
Policy.
Voting Rights. Each outstanding share of our
common stock is entitled to one vote on all matters submitted to
a vote of stockholders.
Preemptive or Similar Rights. Our common stock
is not entitled to preemptive or other similar subscription
rights to purchase any of our securities.
Conversion Rights. Our common stock is not
convertible.
Right to Receive Liquidation
Distributions. Upon our liquidation, dissolution
or winding up, the holders of our common stock are entitled to
receive pro rata our assets which are legally available for
distribution, after payment of all debts and other liabilities
and subject to the prior rights of any holders of preferred
stock then outstanding.
Preferred
Stock
Our board of directors may, without further action by our
stockholders, from time to time, direct the issuance of up to
5,000,000 shares of preferred stock in any series and may,
at the time of issuance, determine the rights, preferences and
limitations of each series. Satisfaction of any dividend
preferences of outstanding shares of preferred stock would
reduce the amount of funds available for the payment of
dividends on shares of common stock. Holders of shares of
preferred stock may be entitled to receive a preference payment
in the event of our liquidation, dissolution or
winding-up
before any payment is made to the holders of shares of common
stock. Under specified circumstances, the issuance of shares of
preferred stock may render more difficult or tend to discourage
a merger, tender offer or proxy contest, the assumption of
control by a holder of a large block of our securities or the
removal of incumbent management. Upon the affirmative vote of a
majority of the total number of directors then in office, the
board of directors, without stockholder approval, may issue
shares of preferred stock with voting and conversion rights
which could adversely affect the holders of shares of common
stock. There are no shares of preferred stock outstanding, and
we have no present intention to issue any shares of preferred
stock.
Registration
Rights
Under our registration rights agreement with the GTCR funds, the
TCW/Crescent funds and members of our management team, holders
of a majority of registrable securities, as defined under the
agreement, have the right, subject to specified conditions, to
request that we register any or all of their securities under
the Securities Act on
Form S-1,
which we refer to as a long-form registration, at
our expense, or on
Form S-3,
which we refer to as a short-form registration, at
our expense. In addition, subject to specified conditions, the
holders of a majority of the TCW/Crescent registrable securities
have the right to request one short-form registration at our
expense. We are not required, however, to effect any long-form
registration within 90 days after the effective date of a
previous long-form
8
registration or a previous registration in which the holders of
registrable securities were given the piggyback rights described
in the following sentence, without any reduction. At our
expense, all holders of registrable securities are entitled to
the inclusion of such securities in any registration statement
used by us to register any offering of our equity securities,
other than pursuant to a registration requested by holders of a
majority of the registrable securities or holders of a majority
of TCW/Crescent registrable securities, an initial public
offering of our equity securities or a registration on
Form S-4
or
Form S-8.
We have registered the shares covered by this prospectus
pursuant to the exercise by the GTCR funds of a demand
registration under the registration rights agreement.
Anti-takeover
Effects of our Certificate of Incorporation and Bylaws
Our amended and restated certificate of incorporation and bylaws
contain certain provisions that are intended to enhance the
likelihood of continuity and stability in the composition of the
board of directors and which may have the effect of delaying,
deferring or preventing a future takeover or change in control
of the company unless such takeover or change in control is
approved by the board of directors.
These provisions include:
Special Meetings of Stockholders. Our amended
and restated certificate of incorporation provides that, except
as otherwise required by law, special meetings of stockholders
can only be called by our chief executive officer or pursuant to
a resolution adopted by a majority of the board of directors.
Stockholders are not permitted to call a special meeting or to
require the board of directors to call a special meeting.
Advance Notice Procedures. Our bylaws
establish an advance notice procedure for stockholder proposals
to be brought before an annual meeting of our stockholders,
including proposed nominations of persons for election to the
board of directors. Stockholders at an annual meeting may only
consider proposals or nominations specified in the notice of
meeting or brought before the meeting by or at the direction of
the board of directors or by a stockholder who was a stockholder
of record on the record date for the meeting, who is entitled to
vote at the meeting and who has given our Secretary timely
written notice, in proper form, of the stockholders
intention to bring that business before the meeting.
In the case of an annual meeting of stockholders, notice by a
stockholder, in order to be timely, must be received at our
principal executive offices not less than 90 days nor more
than 120 days prior to the anniversary date of the
immediately preceding annual meeting of stockholders. In the
event that the annual meeting is called for a date that is not
within 30 days before or 60 days after the anniversary
date, in order to be timely, notice by a stockholder must be
received not later than the tenth day following the earlier of
the date on which notice of the annual meeting was mailed or
public disclosure of the date of the annual meeting was made.
In the case of a special meeting of stockholders called for the
purpose of electing directors, notice by the stockholder, in
order to be timely, must be received not later than the tenth
day following the earlier of the date on which notice of the
date of the special meeting was mailed or public disclosure of
the date of the special meeting was made.
Although the bylaws do not give the board of directors the power
to approve or disapprove stockholder nominations of candidates
or proposals regarding other business to be conducted at a
special or annual meeting, the bylaws may have the effect of
precluding the conduct of certain business at a meeting if the
proper procedures are not followed or may discourage or defer a
potential acquiror from conducting a solicitation of proxies to
elect its own slate of directors or otherwise attempting to
obtain control of the company.
The Delaware General Corporation Law provides generally that the
affirmative vote of a majority of the shares entitled to vote on
any matter is required to amend a corporations certificate
of incorporation or bylaws, unless either a corporations
certificate of incorporation or bylaws require a greater
percentage. Our amended and restated certificate of
incorporation provides that the affirmative vote of holders of
at least 66 2/3% of the total votes eligible to be cast in the
election of directors will be required to amend, alter, change
or repeal our bylaws and specified provisions of our amended and
restated certificate of incorporation. This requirement of a
super-majority vote to approve amendments to our amended and
restated certificate of incorporation and bylaws could enable a
minority of our stockholders to exercise veto power over any
such amendments.
Authorized but Unissued Shares. Our authorized
but unissued shares of common stock and preferred stock are
available for future issuance without stockholder approval,
subject to the requirements of applicable law or regulation,
including any listing requirement of the principal stock
exchange on which our common stock is then
9
listed. These additional shares may be utilized for a variety of
corporate purposes, including future public offerings to raise
additional capital, corporate acquisitions and employee benefit
plans. The existence of authorized but unissued shares of common
stock and preferred stock could render more difficult or
discourage an attempt to obtain control of a majority of our
common stock by means of a proxy contest, tender offer, merger
or otherwise.
Limitation
on Liability and Indemnification of Directors and
Officers
Our amended and restated certificate of incorporation limits the
liability of directors to the fullest extent permitted by the
Delaware General Corporation Law. In addition, our amended and
restated certificate of incorporation provides that we shall
indemnify our directors and officers to the fullest extent
permitted by the Delaware General Corporation Law.
Corporate
Opportunities and Transactions with GTCR
In recognition that directors, officers, stockholders, members,
managers
and/or
employees of GTCR and its affiliates and investment funds
(collectively, the GTCR entities) may serve as our
directors
and/or
officers, and that the GTCR entities and our other non-employee
directors may engage in similar activities or lines of business
that we do, our amended and restated certificate of
incorporation provides for the allocation of certain corporate
opportunities between us and such persons. Specifically, neither
the GTCR entities nor any of our non-employee directors have any
duty to refrain from engaging directly or indirectly in the same
or similar business activities or lines of business that we do.
In the event that any GTCR entity or non-employee director
acquires knowledge of a potential transaction or matter which
may be a corporate opportunity for such persons and us, we do
not have any expectancy in such corporate opportunity, and such
persons do not have any duty to communicate or offer such
corporate opportunity to us and may pursue or acquire such
corporate opportunity for themselves or direct such opportunity
to another person. In addition, if any GTCR entity or
non-employee director acquires knowledge of a potential
transaction or matter which may be a corporate opportunity for
us and such person, we do not have any expectancy in such
corporate opportunity unless such corporate opportunity is
expressly offered to such person solely in his or her capacity
as a director or officer of our company.
In recognition that we may engage in material business
transactions with the GTCR entities, from which we are expected
to benefit, our amended and restated certificate of
incorporation provides that any of our directors or officers who
are also directors, officers, stockholders, members, managers
and/or
employees of any GTCR entity will have fully satisfied and
fulfilled his or her fiduciary duty to us and our stockholders
with respect to such transaction, if:
|
|
|
|
|
the transaction was approved, after being made aware of the
material facts of the relationship between each of Prestige or a
subsidiary thereof and the GTCR entity and the material terms
and facts of the transaction, by (i) an affirmative vote of
a majority of the members of our board of directors who do not
have a material financial interest in the transaction
(Interested Persons) or (ii) an affirmative
vote of a majority of the members of a committee of our board of
directors consisting of members who are not Interested
Person; or
|
|
|
|
the transaction was fair to us at the time we entered into the
transaction; or
|
|
|
|
the transaction was approved by an affirmative vote of the
holders of a majority of shares of our common stock entitled to
vote generally in the election of directors, voting together as
a single class, excluding the GTCR entities and any Interested
Person.
|
Any amendment to the foregoing provisions of our amended and
restated certificate of incorporation requires the affirmative
vote of at least 80% of the voting power of all shares of our
common stock then outstanding.
Transfer
Agent and Registrar
The transfer agent and registrar for our common stock is
Computershare, Ltd.
10
PLAN OF
DISTRIBUTION
The shares covered by this prospectus may be offered and sold
from time to time by the selling stockholders. The term
selling stockholder includes pledgees, donees,
transferees or other successors in interest selling shares
received after the date of this prospectus from each selling
stockholder as a pledge, gift, partnership distribution or other
non-sale related transfer. The number of shares beneficially
owned by a selling stockholder will decrease as and when it
effects any such transfers. The plan of distribution for the
selling stockholders shares sold hereunder will otherwise
remain unchanged, except that the transferees, pledgees, donees
or other successors will be selling stockholders hereunder. To
the extent required, we may amend and supplement this prospectus
from time to time to describe a specific plan of distribution.
The selling stockholders will act independently of us in making
decisions with respect to the timing, manner and size of each
sale. The selling stockholders may make these sales at prices
and under terms then prevailing or at prices related to the then
current market price. The selling stockholders may also make
sales in negotiated transactions. The selling stockholders may
offer their shares from time to time pursuant to one or more of
the following methods:
|
|
|
|
|
ordinary brokerage transactions and transactions in which the
broker-dealer solicits purchasers;
|
|
|
|
one or more block trades in which the broker-dealer will attempt
to sell the shares as agent but may position and resell a
portion of the block as principal to facilitate the transaction;
|
|
|
|
purchases by a broker-dealer as principal and resale by the
broker-dealer for its account;
|
|
|
|
an exchange distribution in accordance with the rules of the
applicable exchange;
|
|
|
|
privately negotiated transactions;
|
|
|
|
through underwriters, brokers or dealers (who may act as agents
or principals) or directly to one or more purchasers;
|
|
|
|
settlement of short sales entered into after the effective date
of the registration statement of which this prospectus is a part;
|
|
|
|
broker-dealers may agree with the selling stockholders to sell a
specified number of such shares at a stipulated price per share;
|
|
|
|
through the writing or settlement of options or other hedging
transactions, whether through an options exchange or otherwise;
|
|
|
|
a combination of any such methods of sale; and
|
|
|
|
any other method permitted pursuant to applicable law.
|
In addition to the foregoing methods, the selling stockholders
may offer their shares from time to time in transactions
involving principals or brokers not otherwise contemplated
above, in a combination of such methods described above or any
other lawful methods. The selling stockholders may also
transfer, donate or assign their shares to lenders, family
members and others and each of such persons will be deemed to be
a selling stockholder for purposes of this prospectus. The
selling stockholders or their successors in interest may from
time to time pledge or grant a security interest in some or all
of the shares of common stock, and if the selling stockholders
default in the performance of their secured obligations, the
pledgees or secured parties may offer and sell the shares of
common stock from time to time under this prospectus; provided,
however, in the event of a pledge or then default on a secured
obligation by the selling stockholder, in order for the shares
to be sold under this registration statement, unless permitted
by law, we must distribute a prospectus supplement and/or
amendment to this registration statement amending the list of
selling stockholders to include the pledgee, secured party or
other successors in interest of the selling stockholder under
this prospectus.
The selling stockholders may also sell their shares pursuant to
Rule 144 under the Securities Act, which permits limited
resale of shares subject to the satisfaction of certain
conditions, including, among other things, the availability of
certain current public information concerning the issuer, the
resale occurring following the required
11
holding period under Rule 144 and the number of shares
being sold during any three-month period not exceeding certain
limitations.
Sales through brokers may be made by any method of trading
authorized by any stock exchange or market on which the shares
may be listed or quoted, including block trading in negotiated
transactions. Without limiting the foregoing, such brokers may
act as dealers by purchasing any or all of the shares covered by
this prospectus, either as agents for others or as principals
for their own accounts, and reselling such shares pursuant to
this prospectus. The selling stockholders may effect such
transactions, directly or indirectly, through underwriters,
broker-dealers or agents acting on their behalf. In effecting
sales, broker-dealers or agents engaged by the selling
stockholders may arrange for other broker-dealers to
participate. Broker-dealers or agents may receive commissions,
discounts or concessions from the selling stockholders, in
amounts to be negotiated immediately prior to the sale (which
compensation as to a particular broker-dealer might be in excess
of customary commissions for routine market transactions).
In offering the shares covered by this prospectus, the selling
stockholders, and any broker-dealers and any other participating
broker-dealers who execute sales for the selling stockholders,
may be deemed to be underwriters within the meaning
of the Securities Act in connection with these sales. Any
profits realized by the selling stockholders and the
compensation of such broker-dealers may be deemed to be
underwriting discounts and commissions.
Our common stock is traded on the New York Stock Exchange under
the symbol PBH.
We, as required by the registration rights agreement between us
and the selling shareholders, will pay substantially all of the
costs, fees and expenses incurred in effecting the registration
of the shares of common stock covered by this prospectus,
including, but not limited to, all registration and filing fees,
fees and expenses of our counsel and our accountants and
reasonable fees and expenses of counsel to the selling
stockholders.
LEGAL
MATTERS
The validity of the common stock offered by this prospectus will
be passed upon for us by Baker, Donelson, Bearman,
Caldwell & Berkowitz, PC, Nashville, Tennessee.
EXPERTS
The financial statements and managements assessment of the
effectiveness of internal control over financial reporting
(which is included in Managements Annual Report on
Internal Control over Financial Reporting) incorporated in this
prospectus by reference to the Annual Report on
Form 10-K
for the year ended March 31, 2006, have been so
incorporated in reliance on the reports of
PricewaterhouseCoopers LLP, an independent registered public
accounting firm, given on the authority of said firm as experts
in auditing and accounting.
INCORPORATION
OF DOCUMENTS BY REFERENCE
The SEC allows us to incorporate by reference
certain of our publicly filed documents into this prospectus,
which means that important information included in such publicly
filed documents is considered part of this prospectus. The
following documents filed by us with the SEC, and any future
documents we file with the SEC under Sections 13(a), 13(c), 14
or 15(d) of the Exchange Act prior to the termination of the
offering, are incorporated by reference into this prospectus:
|
|
|
|
|
our annual report on
Form 10-K
for the fiscal year ended March 31, 2006;
|
|
|
|
our quarterly reports on
Form 10-Q
for the fiscal quarters ended June 30, 2006 and
September 30, 2006;
|
|
|
|
our current reports on
Form 8-K
filed on June 29, 2006, July 14, 2006, August 25,
2006, September 21, 2006, September 27, 2006,
September 29, 2006 and December 22, 2006 (specifically
excluding the information furnished under Items 2.02 or
7.01 and the exhibits furnished thereto);
|
12
|
|
|
|
|
our definitive proxy statement on Schedule 14A filed with
the SEC on July 14, 2006 (with the exception of the Report
of the Compensation Committee, the Performance Graph and the
Report of the Audit Committee, as indicated therein); and
|
|
|
|
the description of our common stock contained in our
Form 8-A
filed with the SEC on February 10, 2005.
|
Any statement contained in a document incorporated or deemed to
be incorporated by reference in this prospectus will be deemed
to be modified or superseded for the purposes of this prospectus
to the extent that a later statement contained herein or in any
other document incorporated or deemed to be incorporated by
reference in this prospectus modifies or supersedes the earlier
statement. Any statement so modified or superseded will not be
deemed, except as so modified or superseded, to constitute a
part of this prospectus.
We will provide at no cost to each person, including any
beneficial owner, to whom this prospectus is delivered, upon
oral or written request of such person, a copy of any or all of
the reports or documents that have been incorporated by
reference in this prospectus, but not delivered with the
prospectus, other than exhibits to such other documents (unless
such exhibits are specifically incorporated by reference into
such documents). We will furnish any exhibit upon the payment of
a specified reasonable fee, which fee will be limited to our
reasonable expenses in furnishing such exhibit. Requests for
such copies should be directed to:
Charles N. Jolly, Esq.
General Counsel and Secretary
Prestige Brands Holdings, Inc.
90 North Broadway
Irvington, New York 10533
Telephone:
(914) 524-6810
These documents may also be accessed through our internet web
site at www.prestigebrandsinc.com or as described under
Where You Can Find More Information.
WHERE YOU
CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement under the
Securities Act with respect to this offering. This prospectus,
which forms a part of the registration statement, does not and
is not required to contain all the information included in the
registration statement and the exhibits and schedules to the
registration statement. For further information about us and our
common stock, you should refer to the registration statement and
its exhibits and schedules. This prospectus summarizes
provisions that we consider material of certain contracts and
other documents to which we refer you. Because any summary may
not contain all of the information that you find important, you
should review the full text of those documents. We have included
copies of those documents as exhibits to the registration
statement, or have provided references to our other SEC filings
for a more complete understanding of the document or matter.
We also currently are subject to the information requirements of
the Exchange Act and in accordance therewith file periodic
reports, proxy statements and other information with the SEC.
You may read and copy (at prescribed rates) any such reports,
proxy statements and other information at the SECs Public
Reference Room at 100 F Street, N.E., Washington, D.C.
20549. For further information concerning the SECs Public
Reference Room, you may call the SEC at
1-800-SEC-0330.
This information may also be accessed on the World Wide Web
through the SECs Internet address at http://www.sec.gov.
Our filings may also be accessed on the World Wide Web through
our Internet address at http://www.prestigebrandsinc.com.
Information on our website is not a part of this prospectus and
is not incorporated in this prospectus by reference.
13
12,650,000 Shares
Prestige Brands Holdings,
Inc.
Common Stock
PROSPECTUS
,
2006
PART II
INFORMATION
NOT REQUIRED IN PROSPECTUS
|
|
Item 14.
|
Other
Expenses of Issuance and Distribution.
|
The following is a statement of the estimated expenses, to be
paid solely by Prestige Brands Holdings, Inc., of the issuance
and distribution of the securities being registered hereby:
|
|
|
|
|
Securities and Exchange Commission
registration fee
|
|
$
|
17,759
|
|
Printing expenses
|
|
|
5,000
|
|
Accounting fees and expenses
|
|
|
20,000
|
|
Legal fees and expenses
|
|
|
20,000
|
|
Blue Sky fees
|
|
|
5,000
|
|
Miscellaneous expenses
|
|
|
17,241
|
|
|
|
|
|
|
Total
|
|
$
|
85,000
|
|
|
|
|
|
|
All amounts shown above are estimates except for the Securities
and Exchange Commission registration fee.
|
|
Item 15.
|
Indemnification
of Directors and Officers.
|
The following is a summary of the statutes, charter and bylaw
provisions or other arrangements under which the
Registrants directors and officers are insured or
indemnified against liability in their capacities as such. All
of the directors and officers of the Registrant are covered by
insurance policies maintained and held in effect by Prestige
Brands Holdings, Inc. against certain liabilities for actions
taken in their capacities as such, including liabilities under
the Securities Act.
Prestige Brands Holdings, Inc. is incorporated under the laws of
the State of Delaware. Section 145 of the General
Corporation Law of the State of Delaware (the Delaware
Statute) provides that a Delaware corporation may
indemnify any persons who are, or are threatened to be made,
parties to any threatened, pending or completed action, suit or
proceeding, whether civil, criminal, administrative or
investigative (a proceeding), other than an action
by or in the right of such corporation, by reason of the fact
that such person is or was an officer, director, employee or
agent of such corporation, or is or was serving at the request
of such corporation as a director, officer, employee or agent of
another corporation or enterprise (an indemnified
capacity). The indemnity may include expenses, including
attorneys fees, judgments, fines and amounts paid in
settlement actually and reasonably incurred by such person in
connection with such action, suit or proceeding, provided such
person acted in good faith and in a manner he reasonably
believed to be in or not opposed to the corporations best
interests and, with respect to any criminal action or
proceeding, had no reasonable cause to believe that his conduct
was illegal. Similar provisions apply to actions brought by or
in the right of the corporation, except that no indemnification
shall be made without judicial approval if the officer or
director is adjudged to be liable to the corporation. Where an
officer or director is successful on the merits or otherwise in
the defense of any action referred to above, the corporation
must indemnify him against the expenses which such officer or
director has actually and reasonably incurred. Section 145
of the Delaware Statute further authorizes a corporation to
purchase and maintain insurance on behalf of any indemnified
person against any liability asserted against him and incurred
by him in any indemnified capacity, or arising out of his status
as such, regardless of whether the corporation would otherwise
have the power to indemnify him under the Delaware Statute.
Article 8 of the Second Amended and Restated Certificate of
Incorporation of Prestige Brands Holdings, Inc. provides that
the corporation may indemnify any person who was or is a party
to any action, suit or proceeding to the fullest extent provided
by the Delaware Statute.
The indemnification rights set forth above shall not be
exclusive of any other right which an indemnified person may
have or hereafter acquire under any statute, provision of our
amended and restated certificate of incorporation, our bylaws,
agreement, vote of stockholders or disinterested directors or
otherwise.
II-1
Reference is made to the attached Exhibit Index, which is
incorporated by reference herein.
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are
being made, a post-effective amendment to this registration
statement:
(i) To include any prospectus required by
Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events
arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental change
in the information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered)
and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of
prospectus filed with the Commission pursuant to
Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than a 20% change in the maximum
aggregate offering price set forth in the Calculation of
Registration Fee table in the effective registration
statement; and
(iii) To include any material information with respect to
the plan of distribution not previously disclosed in the
registration statement or any material change to such
information in the registration statement;
Provided, however, that paragraphs (a)(1)(i), (a)(1)(ii)
and (a)(1)(iii) of this section do not apply if the information
required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to
the Commission by the registrant pursuant to Section 13 or
Section 15(d) of the Securities Exchange Act of 1934 that
are incorporated by reference in the registration statement, or
is contained in a form of prospectus filed pursuant to
Rule 424(b) that is part of the registration statement.
(2) That, for the purpose of determining any liability
under the Securities Act of 1933, each such post-effective
amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of
such securities at that time shall be deemed to be the initial
bona fide offering thereof.
(3) To remove from registration by means of a
post-effective amendment any of the securities being registered
which remain unsold at the termination of the offering.
(4) That, for the purpose of determining liability under
the Securities Act of 1933 to any purchaser:
(i) Each prospectus filed by the registrant pursuant to
Rule 424(b)(3) shall be deemed to be part of the registration
statement as of the date the filed prospectus was deemed part of
and included in the registration statement; and
(ii) Each prospectus required to be filed pursuant to Rule
424(b)(2), (b)(5), or (b)(7) as part of a registration statement
in reliance on Rule 430B relating to an offering made
pursuant to Rule 415(a)(1)(i), (vii), or (x) for the
purpose of providing the information required by
Section 10(a) of the Securities Act of 1933 shall be deemed
to be part of and included in the registration statement as of
the earlier of the date such form of prospectus is first used
after effectiveness or the date of the first contract of sale of
securities in the offering described in the prospectus. As
provided in Rule 430B, for liability purposes of the issuer
and any person that is at that date an underwriter, such date
shall be deemed to be a new effective date of the registration
II-2
statement relating to the securities in the registration
statement to which that prospectus relates, and the offering of
such securities at that time shall be deemed to be the initial
bona fide offering thereof. Provided, however,
that no statement made in a registration statement or prospectus
that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the
registration statement or prospectus that is part of the
registration statement will, as to a purchaser with a time of
contract of sale prior to such effective date, supersede or
modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or
made in any such document immediately prior to such effective
date.
(5) That, for the purpose of determining liability of the
registrant under the Securities Act of 1933 to any purchaser in
the initial distribution of the securities, the undersigned
registrant undertakes that in a primary offering of securities
of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell
the securities to the purchaser: if the securities are offered
or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such
securities to such purchaser:
(i) Any preliminary prospectus or prospectus of the
undersigned registrant relating to the offering required to be
filed pursuant to Rule 424;
(ii) Any free writing prospectus relating to the offering
prepared by or on behalf of the undersigned registrant or used
or referred to by the undersigned registrant;
(iii) The portion of any other free writing prospectus
relating to the offering containing material information about
the undersigned registrant or its securities provided by or on
behalf of the undersigned registrant; and
(iv) Any other communication that is an offer in the
offering made by the undersigned registrant to the purchaser.
(b) Insofar as indemnification for liabilities arising
under the Securities Act of 1933 may be permitted to directors,
officers and controlling persons of the registrant pursuant to
the provisions referred to in Item 15, or otherwise, the
registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is
against public policy as expressed in the Act and is, therefore,
unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the
securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Act and will be
governed by the final adjudication of such issue.
(c) The undersigned registrant hereby undertakes that:
(1) For purposes of determining any liability under the
Securities Act of 1933, the information omitted from the form of
prospectus filed as part of this registration statement in
reliance upon Rule 430A and contained in a form of
prospectus filed by the registrant pursuant to
Rule 424(b)(1) or (4) or 497(h) under the Securities
Act shall be deemed to be part of this registration statement as
of the time it was declared effective.
(2) For the purpose of determining any liability under the
Securities Act of 1933, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered
therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
(d) The undersigned Registrant hereby undertakes that, for
purposes of determining any liability under the Securities Act
of 1933, each filing of the Registrants annual report
pursuant to Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 that is incorporated by reference in the
registration statement shall be deemed to be a new registration
statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on
Form S-3
and has duly caused this Registration Statement to be signed on
its behalf by the undersigned, thereunto duly authorized, in the
City of Irvington, State of New York, on the 28th day of
December, 2006.
PRESTIGE BRANDS HOLDINGS, INC.
|
|
|
|
By:
|
/s/ Peter
J. Anderson
|
Name: Peter J. Anderson
Title: Chief Financial Officer
POWER OF
ATTORNEY
KNOW ALL MEN BY THESE PRESENTS that each person whose signature
appears below constitutes and appoints Peter C. Mann, Peter J.
Anderson and Charles N. Jolly, and each of them, his or her true
and lawful
attorneys-in-fact
and agents, with full power of substitution and resubstitution,
for him or her and in his or her name, place and stead, in any
and all capacities, to execute any and all amendments (including
post-effective amendments) and supplements to this registration
statement and any subsequent registration statement filed
pursuant to Rule 462(b) under the Securities Act of 1933,
as amended, and to file the same, with all exhibits thereto, and
other documents in connection therewith, with the Securities and
Exchange Commission, granting unto said
attorneys-in-fact
and agents, and each of them, full power and authority to do and
perform each and every act and thing requisite and necessary to
be done in and about the premises, as fully to all intents and
purposes as he or she might or could do in person, hereby
ratifying and confirming all that said
attorneys-in-fact
and agents or any of them, or their, or his or her substitute or
substitutes, may lawfully do or cause to be done by virtue
hereof.
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement and power of attorney have been signed by
the following persons in the capacities indicated on the
28th day of December, 2006.
|
|
|
|
|
Signature
|
|
Capacity
|
|
/s/ Peter
C. Mann
Peter
C. Mann
|
|
Chairman of the Board, Chief
Executive Officer & President (principal executive
officer)
|
|
|
|
/s/ Peter
J. Anderson
Peter
J. Anderson
|
|
Chief Financial Officer (principal
financial and accounting officer)
|
|
|
|
L.
Dick Buell
|
|
Director
|
|
|
|
/s/ John
E. Byom
John
E. Byom
|
|
Director
|
|
|
|
/s/ Gary
E. Costley
Gary
E. Costley
|
|
Director
|
|
|
|
David
A. Donnini
|
|
Director
|
II-4
|
|
|
|
|
Signature
|
|
Capacity
|
|
/s/ Ronald
B. Gordon
Ronald
B. Gordon
|
|
Director
|
|
|
|
Vincent
J. Hemmer
|
|
Director
|
|
|
|
/s/ Patrick
M. Lonergan
Patrick
M. Lonergan
|
|
Director
|
|
|
|
Raymond
P. Silcock
|
|
Director
|
II-5
EXHIBIT INDEX
|
|
|
|
|
EXHIBIT
|
|
|
NO.
|
|
DESCRIPTION
|
|
|
2
|
.1
|
|
Asset Sale and Purchase Agreement,
dated July 22, 2005, by and among Reckitt Benckiser Inc.,
Reckitt Benckiser (Canada) Inc., Prestige Brands Holdings, Inc.
and The Spic and Span Company (filed as Exhibit 2.1 to
Prestige Brands Holdings, Inc.s
Form 8-K
filed on July 28, 2005).+
|
|
2
|
.2
|
|
Unit Purchase Agreement, dated as
of November 9, 2005, by and between Prestige Brands
Holdings, Inc., and each of Dental Concepts, LLC, Richard
Gaccione, Combined Consultants DBPT Gordon Wade, Douglas A.P.
Hamilton, Islandia L.P., George ONeill, Abby ONeill,
Michael Porter, Marc Cole and Michael Lesser (filed as
Exhibit 10.1 to Prestige Brands Holdings, Inc.s
Form 10-Q
filed on February 14, 2006).+
|
|
2
|
.3
|
|
Stock Sale and Purchase Agreement,
dated as of September 21, 2006, by Lil Drug Store
Products, Inc., Wartner USA B.V., Lil Drug Store Products,
Inc.s shareholders set forth on the signature page
attached thereto, and Medtech Products Inc. (filed as
Exhibit 2.1 to Prestige Brands Holdings, Inc.s
Form 10-Q
filed on November 9, 2006).+
|
|
4
|
.1
|
|
Form of stock certificate for
common stock (filed as Exhibit 4.1 to Prestige Brands
Holdings, Inc.s
Form S-1/A
filed on January 26, 2005).+
|
|
4
|
.2
|
|
Indenture, dated April 6,
2004, among Prestige Brands, Inc., each Guarantor thereto and
U.S. Bank National Association, as Trustee (filed as
Exhibit 4.1 to Prestige Brands, Inc.s
Form S-4
filed on July 6, 2004).+
|
|
4
|
.3
|
|
Form of
91/4% Senior
Subordinated Note due 2012 (contained in Exhibit 4.2 to
this Registration Statement).+
|
|
5
|
.1
|
|
Form of Opinion of Baker,
Donelson, Bearman, Caldwell & Berkowitz, PC **
|
|
23
|
.1
|
|
Consent of PricewaterhouseCoopers
LLP.*
|
|
23
|
.2
|
|
Consent of Baker, Donelson,
Bearman, Caldwell & Berkowitz, PC (included in
Exhibit 5.1)
|
|
24
|
.1
|
|
Powers of Attorney (included in
Part II to the Registration Statement)
|
|
|
|
* |
|
Filed herewith. |
|
** |
|
To be filed by amendment or by a report filed under the
Securities Exchange Act of 1934, as amended, and incorporated
herein by reference. |
|
+ |
|
Incorporated herein by reference. |
Ex-5.1 Baker, Donelson Opinion
Exhibit 5.1
[BAKER,
DONELSON, BEARMAN, CALDWELL & BERKOWITZ, P.C. LETTERHEAD]
December 28, 2006
Prestige Brands Holdings, Inc.
90 North Broadway
Irvington, New York 10533
|
Re: |
|
Registration Statement on Form S-3 |
Ladies and Gentlemen:
We have acted as counsel to Prestige Brands Holdings, Inc, a Delaware corporation (the
Registrant), in connection with a Registration Statement
on Form S-3 (the Registration
Statement) filed by the Registrant with the Securities and Exchange Commission pursuant to the
Securities Act of 1933, as amended (the Securities Act),
relating to the resale (the Offering) of
12,650,000 shares (the Shares) of the Companys common stock $0.01 par value per share (the
Common Stock) being sold by certain selling stockholders listed in the Registration Statement
(each a, Selling Stockholder). This opinion letter is furnished to you at your request to enable you to fulfill the
requirements of Item 601(b)(5) of Regulation S-K in connection with the Registration Statement.
In connection with this opinion, we have examined and relied on originals, or copies certified
or otherwise identified to our satisfaction, of such documents and records of the Company,
certificates and representations of officers of the Company, and other documents and records as we
have deemed necessary or appropriate to enable us to render the opinions expressed herein. We have
assumed the genuineness of all signatures on such documents and records, the legal capacity of all
natural persons whose signatures appear on such documents and records, the authenticity of all
documents and records submitted to us as originals, the conformity to authentic original documents
and records of all documents and records submitted to us as copies, and the truthfulness of all
statements of fact contained therein. We have not independently verified any factual matters
relating to this opinion. We have made such investigations of law as we have deemed necessary and
relevant as a basis hereof.
Based on the foregoing, subject to the limitations and assumptions set forth herein, and
having due regard for such legal consideration as we deem relevant, we are of the opinion that the
Shares to be sold by the Selling Stockholders are legally issued, fully paid, and nonassessable.
This opinion letter has been prepared solely in connection with the filing of the Registration
Statement.
We
hereby consent to the filing of this opinion letter as an exhibit to
the Registration Statement and to the reference to our firm under
the caption Legal Matters in the prospectus forming a
part thereof. In giving such consent, we do not thereby concede that
we are within the category of persons whose consent is required
under Section 7 of the Securities Act or the rules and regulations of
the Commission promulgated thereunder.
Very
truly yours,
Ex-23.1 PricewaterhouseCoopers Consent
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby
consent to the incorporation by reference in this Registration
Statement on Form S-3 of
our reports dated June 10, 2006 relating to the financial statements, financial statement schedule,
managements assessment of the effectiveness of internal control over financial reporting and the
effectiveness of internal control over financial reporting which appear in Prestige Brands Holdings, Inc.s Annual
Report on Form 10-K for the year ended
March 31, 2006. We also consent to the reference to us under the heading Experts in such Registration
Statement.
/s/ PricewaterhouseCoopers LLP
Salt Lake City, UT
December 27, 2006